Mali

DEVEX    by  By Jenny Lei Ravelo                        March 19, 2015
Emergency operation centers have been critical in stemming potential Ebola outbreaks in several West African countries like Nigeria and Mali, but there remain doubts about whether countries would keep them post-Ebola. Ismail Ould Cheikh Ahmed, special representative of the secretary-general and head of the U.N. Mission for Ebola Emergency Response, meets with UNMEER staff at the Ebola Operation Center in Bamako, Mali. Should EOCs be retained post-Ebola? Photo by: Pierre Peron / UNMEER / CC BY-ND

This is largely because of its potential to cause “institutional turf wars” within the government structure, according to Madji Sock, partner at global development advisory firm Dalberg.

WORLD HEALTH ORGANIZATION MEDIA CENTRE                   Jan, 15, 2015

One year after the first Ebola cases started to surface in Guinea, WHO is publishing this series of 14 papers that take an in-depth look at West Africa’s first epidemic of Ebola virus disease.

The papers explore reasons why the disease evaded detection for several months and the factors, many specific to West Africa, that fuelled its subsequent spread.

The most extensive papers trace events in each of the 3 most severely affected countries – Guinea, Liberia and Sierra Leone...

Key events are set out chronologically, starting with the child who is believed to be the index case of this epidemic through to the Director-General’s commitment to steadfastly support affected countries until they reach zero cases.

Read complete news release

http://www.who.int/mediacentre/news/notes/2015/ebola-one-year-on/en/
-0-

Read report:

In-Depth report on lessons to be learned from the Ebola crisis

THE WASHINGTON POST by By Lena H. Sun, Brady Dennis and Joel Achenbach                            Dec. 29, 2014

A year after it began, the Ebola epidemic in West Africa continues to be unpredictable, forcing governments and aid groups to improvise strategies as they chase a virus that is unencumbered by borders or bureaucracy.

The people fighting Ebola are coming up with lists of lessons learned — not only for the current battle, which has killed more than 7,500 people and is far from over, but also for future outbreaks of deadly contagions.

Alice Jallabah, head of a bushmeat seller group, holds dried bushmeat in Monrovia. (Zoom Dosso/AFP/Getty Images)

REUTERS                                                                                              Dec. 19, 2014

GENEVA –  Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

The World Health Organization, which hosted a meeting of national regulatory authorities and ethics committees earlier this week, said they had thoroughly discussed all aspects of the proposed trials at the two-day meeting.

"Reviewing countries requested additional documentation from the manufacturer of the vaccine, GlaxoSmithKline, before authorization of the trials," the WHO said in a statement.

Countries where the trials are planned -- Cameroon, Ghana, Mali, Nigeria and Senegal -- should receive and review the additional information by the end of January.

"If these steps are completed to the satisfaction of the national authorities, Phase II trials are likely to begin in February," the statement said.

The GSK vaccine is already undergoing Phase I trials, to check its safety in humans, in Switzerland, Britain, Mali and the United States, and is one of the two leading candidate vaccines for Ebola already undergoing tests.